Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 3;7(5):e008268. doi: 10.1161/JAHA.117.008268

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Natriuretic peptides and neprilysin activity. Circulating natriuretic peptide levels, including brain natriuretic peptide (BNP), at 8 and 12 weeks after myocardial ischemia/reperfusion (4 and 8 weeks after valsartan or sacubitril/valsartan [also known as LCZ696] therapy, respectively). A, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide; pg/mL) at 8 weeks. B, NT‐proBNP (pg/mL) at 12 weeks. C, BNP (ng/mL) at 8 weeks. D, BNP (ng/mL) at 12 weeks. E, Bradykinin levels (pg/mL) at 8 weeks. F, Bradykinin levels (ng/mL) at 12 weeks. G, Neprilysin activity as measured in relative fluorescence units (RFU/min per mg) at 8 weeks.. H, Neprilysin activity (RFU/min per mg) at 12 weeks. I, Myocardial gene expression at 12 weeks. Animal numbers are shown in white circles. NS indicates not significant. *P<0.05, **P<0.01.